Astellas’ AML therapy bests chemo in Phase 3 study
In a Phase 3 trial, Astellas’ Xospata improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) compared to chemotherapy, according to ...
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.